Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16446576 | 0.82 | CHKA (0.37) | LMNAMAPT | |
| SCHEMBL9804027 | 0.78 | NOTUM (0.42) | LMNAMAPTCYP19A1NOTUM | |
| SCHEMBL1970934 | 0.77 | NOTUM (0.45) | CYP3A4KDM4EHPGDGAALMNA | |
| SCHEMBL16446130 | 0.74 | CYP1A2 (0.44) | POLBGAALMNAMAPT | |
| SCHEMBL535441 | 0.72 | SMN1; SMN2 (0.40) | POLBKDM4EGAALMNA | |
| SCHEMBL535848 | 0.71 | BCHE (0.38) | KDM4ELMNAMAPTNOTUM | |
| SCHEMBL16446572 | 0.70 | L3MBTL1 (0.40) | POLBKDM4EGAAMAPT | |
| SCHEMBL16446609 | 0.67 | MGLL (0.42) | POLBKDM4EHPGDGAALMNA | |
| SCHEMBL1916262 | 0.67 | KCNH2 (0.31) | LMNA | |
| SCHEMBL535613 | 0.65 | MALT1 (0.36) | KDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| EP-4247376-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Denali Therapeutics Inc. (US) | 2023-09-27 | — | — | EP | claimed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | claimed |
| CN-114933758-A | Quantum dot thin film material with gas-sensitive performance and application thereof | 江苏烨湫传感科技有限公司 | 2022-08-23 | — | — | CN | claimed |
| CN-114540024-A | Perovskite quantum dot material with gas-sensitive property and application thereof | 江苏烨湫传感科技有限公司 | 2022-05-27 | — | — | CN | claimed |
| WO-2022109268-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2022-05-27 | — | — | WO | claimed |
| US-RE48841-E1 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2021-12-07 | — | — | US | claimed |
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | claimed |
| US-9670208-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-06 | — | — | US | claimed |
| EP-3089980-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-11-09 | — | — | EP | claimed |
| EP-0796857-A1 | 4-thia-1-azabicyclo(3.2.0)heptane-3-imino-2-isopropylidene-7-oxo analogons of beta-lactams, processes for their preparation and the use thereof | PLIVA farmaceutska, kemijska, prehrambena i kozmeticka industrija, dionicko drustvo (HR) | 1997-09-24 | — | — | EP | claimed |
| EP-0659177-A1 | 4-OXO-AZETIDINE-2-SULPHONIC ACID AMIDES AND THEIR SALTS, PROCESS FOR THEIR PRODUCTION AND THEIR USE | PLIVA Handels GmbH (DE) | 1995-06-28 | — | — | EP | claimed |
| WO-1994005632-A1 | 4-OXO-AZETIDINE-2-SULPHONIC ACID AMIDES AND THEIR SALTS, PROCESS FOR THEIR PRODUCTION AND THEIR USE | PLIVA HANDELS GMBH (DE) | 1994-03-17 | — | — | WO | claimed |
| US-5185027-A | Salicylaldehyde derivatives and salicyclic acid derivatives and their sulfur analogs, and their use as herbicides and bioregulators | BASF AKTIENGESELLSCHAFT (DE) | 1993-02-09 | — | — | US | claimed |
| US-5085686-A | Plant growth regulator | BASF AKTIENGESELLSCHAFT (DE) | 1992-02-04 | — | — | US | claimed |
| US-5026848-A | Antirhinovirus agents | SYNPHAR LABORATORIES INCORPORATED (CA) | 1991-06-25 | — | — | US | claimed |
| EP-0335636-A1 | Antiviral compounds | SYNPHAR LABORATORIES INC. (CA) | 1989-10-04 | — | — | EP | claimed |
| US-4853404-A | DIURETIS, SALURETICS, URICOSURETICS | TANABE SEIYAKU CO., LTD. (JP) | 1989-08-01 | — | — | US | claimed |
| EP-0268800-A1 | Phenoxyacetic acid derivatives and processes for preparing the same | Tanabe Seiyaku Co., Ltd. (JP) | 1988-06-01 | — | — | EP | claimed |
| CN-87106895-A | Phenoxyacetic acid derivatives and process for producing the same | — | 1988-04-20 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416205-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NLRP3, NLRP1, NOD1 | POLB 3627/4885CYP3A4 3054/4885KDM4E 3822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.